These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1193 related articles for article (PubMed ID: 31484063)
1. The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. Yang WH; Ding CC; Sun T; Rupprecht G; Lin CC; Hsu D; Chi JT Cell Rep; 2019 Sep; 28(10):2501-2508.e4. PubMed ID: 31484063 [TBL] [Abstract][Full Text] [Related]
2. A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer. Yang WH; Huang Z; Wu J; Ding CC; Murphy SK; Chi JT Mol Cancer Res; 2020 Jan; 18(1):79-90. PubMed ID: 31641008 [TBL] [Abstract][Full Text] [Related]
3. Hippo pathway effectors YAP/TAZ as novel determinants of ferroptosis. Yang WH; Chi JT Mol Cell Oncol; 2020; 7(1):1699375. PubMed ID: 31993503 [TBL] [Abstract][Full Text] [Related]
4. Roles of YAP/TAZ in ferroptosis. Magesh S; Cai D Trends Cell Biol; 2022 Sep; 32(9):729-732. PubMed ID: 35701310 [TBL] [Abstract][Full Text] [Related]
5. DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway. Lin CC; Yang WH; Lin YT; Tang X; Chen PH; Ding CC; Qu DC; Alvarez JV; Chi JT Oncogene; 2021 Mar; 40(11):2018-2034. PubMed ID: 33603168 [TBL] [Abstract][Full Text] [Related]
6. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy. Zhu J; Wu T; Lin Q Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351 [TBL] [Abstract][Full Text] [Related]
7. The Hippo Pathway Effector YAP Promotes Ferroptosis via the E3 Ligase SKP2. Yang WH; Lin CC; Wu J; Chao PY; Chen K; Chen PH; Chi JT Mol Cancer Res; 2021 Jun; 19(6):1005-1014. PubMed ID: 33707306 [TBL] [Abstract][Full Text] [Related]
8. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ). Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650 [TBL] [Abstract][Full Text] [Related]
9. Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications. Sun T; Chi JT Genes Dis; 2021 May; 8(3):241-249. PubMed ID: 33997171 [TBL] [Abstract][Full Text] [Related]
10. Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor. Vargas RE; Duong VT; Han H; Ta AP; Chen Y; Zhao S; Yang B; Seo G; Chuc K; Oh S; El Ali A; Razorenova OV; Chen J; Luo R; Li X; Wang W EMBO J; 2020 Jan; 39(1):e102406. PubMed ID: 31782549 [TBL] [Abstract][Full Text] [Related]
11. YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells. White SM; Avantaggiati ML; Nemazanyy I; Di Poto C; Yang Y; Pende M; Gibney GT; Ressom HW; Field J; Atkins MB; Yi C Dev Cell; 2019 May; 49(3):425-443.e9. PubMed ID: 31063758 [TBL] [Abstract][Full Text] [Related]
12. Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma. Yangyun W; Guowei S; Shufen S; Jie Y; Rui Y; Yu R Gene; 2022 Jan; 809():145992. PubMed ID: 34648917 [TBL] [Abstract][Full Text] [Related]
13. RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation. Chen P; Duan Y; Lu X; Chen L; Zhang W; Wang H; Hu R; Liu S Cancer Immunol Immunother; 2021 Nov; 70(11):3261-3275. PubMed ID: 33837850 [TBL] [Abstract][Full Text] [Related]
14. YAP/TAZ-mediated regulation of laminin 332 is enabled by β4 integrin repression of ZEB1 to promote ferroptosis resistance. Goel HL; Karner ER; Kumar A; Mukhopadhyay D; Goel S; Mercurio AM J Biol Chem; 2024 Apr; 300(4):107202. PubMed ID: 38508310 [TBL] [Abstract][Full Text] [Related]
15. New insights into the ambivalent role of YAP/TAZ in human cancers. Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598 [TBL] [Abstract][Full Text] [Related]
16. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway. Jang JW; Kim MK; Bae SC Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552 [TBL] [Abstract][Full Text] [Related]
17. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1. Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213 [TBL] [Abstract][Full Text] [Related]
19. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells. Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487 [TBL] [Abstract][Full Text] [Related]
20. Emerging Role of Hippo-YAP (Yes-Associated Protein)/TAZ (Transcriptional Coactivator with PDZ-Binding Motif) Pathway Dysregulation in Renal Cell Carcinoma Progression. Mondal V; Higgins PJ; Samarakoon R Cancers (Basel); 2024 Aug; 16(15):. PubMed ID: 39123485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]